Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Total Non-Current Liabilities (2016 - 2025)

Celldex Therapeutics has reported Total Non-Current Liabilities over the past 16 years, most recently at $51.8 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $51.8 million for Q4 2025, up 23.68% from a year ago — trailing twelve months through Dec 2025 was $51.8 million (up 23.68% YoY), and the annual figure for FY2025 was $51.8 million, up 23.68%.
  • Total Non-Current Liabilities for Q4 2025 was $51.8 million at Celldex Therapeutics, up from $47.5 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for CLDX hit a ceiling of $51.8 million in Q4 2025 and a floor of $15.4 million in Q1 2022.
  • Median Total Non-Current Liabilities over the past 5 years was $27.6 million (2024), compared with a mean of $27.5 million.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 104.19% in 2022 and later tumbled 46.61% in 2023.
  • Celldex Therapeutics' Total Non-Current Liabilities stood at $17.8 million in 2021, then increased by 18.93% to $21.2 million in 2022, then skyrocketed by 51.21% to $32.1 million in 2023, then soared by 30.6% to $41.9 million in 2024, then rose by 23.68% to $51.8 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $51.8 million (Q4 2025), $47.5 million (Q3 2025), and $34.5 million (Q2 2025) per Business Quant data.